Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Porphyria Cutanea Tarda based on clinical exam and 24-hour urine porphyrin levels~* have Porphyria Cutanea Tarda for at least 3 months prior to enrollment with active blistering (3 blisters or erosions per month)~* women of childbearing potential must use an effective method of contraception during the study, however this cannot include hormonal contraception (oral contraceptives, hormone patches, Depo-Provera injections, NUVA Ring, etc.)~* treatment naive patients or patients unresponsive or intolerant of phlebotomy~* Ferritin level is greater than or equal to 25ng/mL~Exclusion Criteria:~* patients with serum creatinine above the upper limit of normal~* patients receiving phlebotomy who are controlled on this therapy~* pregnant or breast feeding females~* patients with liver transaminases more than 5 times the upper limit of normal~* patients with a history of hypersensitivity to deferasirox~* patients with a history of pre-existing renal condition, or receiving medication that depresses renal function~* patients on other chelators~* history of non-compliance to medical regimens.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).